|
|
Post by shawnonafrezza on Mar 1, 2021 22:17:55 GMT -5
Doesn’t matter what brought the share price down or what was manipulated, it was a blindside, which damages the technicals and damages the sentiment. The leaseback gave the look of not needing money at this time. Of course that’s why they go to Wainwright and the like...they go to raise money and make deals after the conference but usually that takes three weeks so this seems to be a different circumstance. You're probably closest to the typical Afrezza consumer - what are the barriers (still)?
Is it too hard to convince docs to consider it? Is it too hard to get insurance coverage with the PA? W/out ins coverage, is it far too expensive for a cash pay patient? A combination of these or all of the above?
My $0.02 because I just went through all of this again. - On getting docs to consider it, I actually gave up. I've done it 4 times (I think) and just called VDEX instead now that they do tele appointments. So more clinics like that would help. I've been here long enough so I hope I don't get called a shrill but honestly VDEX knows what they're doing better than anyone else. They know dosing better (I've used Afrezza for 4.5 years and they taught me new things), they know coverage better, they know all of it better. - Most docs don't write too many PAs. They can go back and forth a lot and are tiring. FWIW, VDEX had it all covered in 1 week which is a record but that could also be that I have the best insurance I've ever had. They do recommend eagle pharmacy as well to get around the PA. - I said it in another post and someone (I forget who) just gave some really insensitive (we can't all lose 300k in a day investing and roll it off) that yes, Afrezza is expensive. Eagle route is probably $400/month for your average diabetic which makes the PA route w/ coupon card (or straight coverage) what you want but it's harder. Coverage has gotten better than it was when I first used it in 2016. |
|
|
|
Post by cretin11 on Mar 1, 2021 22:48:52 GMT -5
awesomo you know the playbook with some on here: whenever share price goes down it is simply because of the nefarious and hidden shorts, including those lurking on this site (you? me? baba? anyone else who dares post any criticism?), never because of a dilutive action taken by the company or any other reason. I think the GME fiasco showed just how being "nefarious, hidden and lurking' can jeopardize one's financial well being. I don't think for a minute any of you are die hard shorts....you have to have diamond balls to do that as the risk is unlimited. Some posters here strike me as more of the 'retail' mom and pop crowd, "opportunistic bunch", the working stiffs in Midtown and Uptown don't waste their time on five dollar stock message boards. Totally agree, there are no paid shorts on this board trying to influence and manipulate the stock. It’s a conspiracy theory, myth, etc. |
|
|
|
Post by cretin11 on Mar 1, 2021 22:59:31 GMT -5
You're probably closest to the typical Afrezza consumer - what are the barriers (still)?
Is it too hard to convince docs to consider it? Is it too hard to get insurance coverage with the PA? W/out ins coverage, is it far too expensive for a cash pay patient? A combination of these or all of the above?
My $0.02 because I just went through all of this again. - On getting docs to consider it, I actually gave up. I've done it 4 times (I think) and just called VDEX instead now that they do tele appointments. So more clinics like that would help. I've been here long enough so I hope I don't get called a shrill but honestly VDEX knows what they're doing better than anyone else. They know dosing better (I've used Afrezza for 4.5 years and they taught me new things), they know coverage better, they know all of it better. - Most docs don't write too many PAs. They can go back and forth a lot and are tiring. FWIW, VDEX had it all covered in 1 week which is a record but that could also be that I have the best insurance I've ever had. They do recommend eagle pharmacy as well to get around the PA. VDEX has dialed that part in, better than anyone else. It would be be easy to give up on Afrezza because of MannKind’s sales and marketing failures. Script numbers are abysmal under any metric. VDEX provides some hope because Afrezza is such an amazing treatment, and VDEX has developed the best way to educate patients and insurers about it. Even still we are basically treading water and hoping for a breakthrough, or enough traction to get over the inflection point. |
|
|
|
Post by celo on Mar 2, 2021 0:50:58 GMT -5
For what it's worth which isn't much on my chart, MNKD bounced off my lower boundary at 4. It will probably break through that tomorrow and figuring out a new bottom will be very difficult.
Who ever posted the head and shoulders thing that I poo poo'd, well, all you need is a shoulder now. Nice work.
|
|
|
|
Post by sweedee79 on Mar 2, 2021 4:21:02 GMT -5
Doesn’t matter what brought the share price down or what was manipulated, it was a blindside, which damages the technicals and damages the sentiment. The leaseback gave the look of not needing money at this time. Of course that’s why they go to Wainwright and the like...they go to raise money and make deals after the conference but usually that takes three weeks so this seems to be a different circumstance. "The leaseback gave the look of not needing money at this time." Sports - I saw it very differently. The leaseback seems to be an act of desperation, albeit intended to extend life as a bridge until hoped-for future revenues. The leaseback is not as painful short-term for shareholders (being non-dilutive) but any established biotech that is selling its manufacturing facility for operating funds is on its last legs.
Maybe the miracle will continue and MNKD stays alive...but the reason for all this is that Afrezza has not been successful as a prandial insulin product.
You're probably closest to the typical Afrezza consumer - what are the barriers (still)?
Is it too hard to convince docs to consider it? Is it too hard to get insurance coverage with the PA? W/out ins coverage, is it far too expensive for a cash pay patient? A combination of these or all of the above?
What I saw with my dad is that doctors did NOT understand Afrezza... They didn't understand the dosing.. they didn't understand the fast in fast out.. also they didn't want to go through the trouble of having to understand it.. were comfortable with what they were doing already and according to our SOC didn't feel the need to change. Our doctor complained about the paper work she had to do for the spiro.. and writing to insurance etc.. Medical profession is overworked.. never enough time and tons of paperwork now days... Afrezza never had a chance to shine.. it wasn't given one.. |
|
|
|
Post by Clement on Mar 2, 2021 9:47:35 GMT -5
9:46 am
Over 3M in volume!!!
|
|
|
|
Post by longliner on Mar 2, 2021 10:13:41 GMT -5
At this rate we will hit 10 million in the first hour of trading! Shortie meet buyer....buyer meet shortie.
|
|
|
|
Post by peppy on Mar 2, 2021 10:27:36 GMT -5
volume at 50 mins of trade. real time, 3,865,053 summary, 7,181,598 Avg. Volume 5,666,83 price bottom, now going up. finance.yahoo.com/quote/MNKD?p=MNKDwww.nasdaq.com/market-activity/stocks/mnkd/real-time3.90-0.11 (-2.7431%) As of 10:23AM EST. Market open. That was hellish.   The 20 week MA. the weekly MA's still lining up. I'll take it as the pull back. Look at NK's chart as it was going up. Sharp pull backs along the way. Get the money right. MNKD besides Afrezza has joined a respiratory team. Coming out of COVID respiratory focus doesn't hurt. So Afrezza, and now respiratory meds. The UTHR pipeline starts soon. Back to NK, see the pull backs along the way? See the time line?  |
|
|
|
Post by longliner on Mar 2, 2021 10:30:22 GMT -5
Now that was a big buy!!!!! 1.05 million shares! Run Forest run!!
|
|
|
|
Post by straightly on Mar 2, 2021 10:48:18 GMT -5
volume at 50 mins of trade. real time, 3,865,053 summary, 7,181,598 Avg. Volume 5,666,83 price bottom, now going up. finance.yahoo.com/quote/MNKD?p=MNKDwww.nasdaq.com/market-activity/stocks/mnkd/real-time3.90-0.11 (-2.7431%) As of 10:23AM EST. Market open. That was hellish. The 20 week MA. the weekly MA's still lining up. I'll take it as the pull back. Look at NK's chart as it was going up. Sharp pull backs along the way. Get the money right. MNKD besides Afrezza has joined a respiratory team. Coming out of COVID respiratory focus doesn't hurt. So Afrezza, and now respiratory meds. The UTHR pipeline starts soon. Back to NK, see the pull backs along the way? See the time line? The goddess of quant: my hunches say green for today, what say you? |
|
|
|
Post by longliner on Mar 2, 2021 11:03:21 GMT -5
If they can push it down to $3.86 again let's see another 1 million share buy. That would pucker them up!
|
|
|
|
Post by straightly on Mar 2, 2021 11:40:33 GMT -5
peppy: is there a name for “hammer down, grind up, and repeat” pattern?
|
|
|
|
Post by peppy on Mar 2, 2021 11:59:59 GMT -5
peppy : is there a name for “hammer down, grind up, and repeat” pattern? The Hammer me down, clobber me. It takes money to make money theory.  |
|
|
|
Post by radgray68 on Mar 2, 2021 12:13:53 GMT -5
For what it's worth which isn't much on my chart, MNKD bounced off my lower boundary at 4. It will probably break through that tomorrow and figuring out a new bottom will be very difficult. Who ever posted the head and shoulders thing that I poo poo'd, well, all you need is a shoulder now. Nice work. It was I who posted about the head and shoulders top formation. There's just too much time between here and actual profitability. I really wish I was wrong on this one but recognizing patterns is kinda my thing. It helped that we were pushed up in the $6-7 range once before when this same type of cash raise event happened. Setting my buy at $2.00. |
|
|
|
Post by sportsrancho on Mar 2, 2021 12:22:32 GMT -5
My $0.02 because I just went through all of this again. - On getting docs to consider it, I actually gave up. I've done it 4 times (I think) and just called VDEX instead now that they do tele appointments. So more clinics like that would help. I've been here long enough so I hope I don't get called a shrill but honestly VDEX knows what they're doing better than anyone else. They know dosing better (I've used Afrezza for 4.5 years and they taught me new things), they know coverage better, they know all of it better. - Most docs don't write too many PAs. They can go back and forth a lot and are tiring. FWIW, VDEX had it all covered in 1 week which is a record but that could also be that I have the best insurance I've ever had. They do recommend eagle pharmacy as well to get around the PA. VDEX has dialed that part in, better than anyone else. It would be be easy to give up on Afrezza because of MannKind’s sales and marketing failures. Script numbers are abysmal under any metric. VDEX provides some hope because Afrezza is such an amazing treatment, and VDEX has developed the best way to educate patients and insurers about it. Even still we are basically treading water and hoping for a breakthrough, or enough traction to get over the inflection point. It’s time.... for some cooperation from Mannkind and a meeting of the minds on the protocols for Afrezza. It’s badly needed and it’s what’s holding us back, we need to keep the patients on the product and Vdex does that. We administer it every day so we have that gained knowledge that’s priceless. |
|
